Current Trends in The Use of Liposomes for Tumor Targeting

Deshpande, Pranali P.; Biswas, Swati; Torchilin, Vladimir P.

doi:10.2217/nnm.13.118

Cited by 561 publications

(375 citation statements)

References 135 publications

Supporting

Mentioning

354

Contrasting

Unclassified

Order By: Relevance

“…When autophagy occurs, a phagophore isolates cytoplasmic material (7) and closes on itself to form an autophagosome (8). These fuse with lysosomes to form an autolysosome (9) in which the cytoplasmic cargo is degraded. In this research article, nanoparticles are directly delivered to the cytoplasm of the cells by microinjection (10).…”

Section: Fig1mentioning

confidence: 99%

See 1 more Smart Citation

Lysosomal capturing of cytoplasmic injected nanoparticles by autophagy: An additional barrier to non viral gene delivery

Remaut

Oorschot²,

Braeckmans

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

Autophagy or 'self-eating' is a process by which defective organelles and foreign material can be cleared from the cell's cytoplasm and delivered to the lysosomes in which degradation occurs. It remains an open question, however, whether nanoparticles that did not enter the cell through endocytosis can also be captured from the cytoplasm by autophagy. We demonstrate that nanoparticles that are introduced directly in the cytoplasm of the cells by microinjection, can trigger an autophagy response. Moreover, both polystyrene beads and plasmid DNA containing poly-ethylene-imine complexes colocalize with autophagosomes and lysosomes, as was confirmed by electron microscopy.This indicates that cytoplasmic capturing of nanoparticles can occur by an autophagy response. The capturing of nanoparticles from the cytoplasm most likely limits the time frame in which efficient nucleic acid delivery can be obtained. Hence, autophagy forms an additional barrier to non-viral gene delivery, a notion that was not often taken into account before. Furthermore, these findings urges us to reconsider the idea that a single endosomal escape event is sufficient to have the long-lasting presence of nanoparticles in the cytoplasm of the cells.

show abstract

Section: Fig1mentioning

confidence: 99%

“…Since more than a decade, pharmacists, material scientists and biophysicists are intensively studying the design, preparation and cell biological behavior of nanosized particles carrying nucleic acids (2)(3)(4)(5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Lysosomal capturing of cytoplasmic injected nanoparticles by autophagy: An additional barrier to non viral gene delivery

Remaut

Oorschot²,

Braeckmans

et al. 2014

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Furthermore, the use of liposomal nanoparticles has been shown to have no discernible impact on the characteristics of the entrapped drug 31 . Previous studies in this area have indicated that the trans-activating factor (TAT) could promote the cell internalization capability of liposomal nanoparticles 32,33 .…”

Section: Discussionmentioning

confidence: 99%

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

et al. 2014

View full text Add to dashboard Cite

Specific targeting and cellular internalization are key properties for carriers of antitumor therapeutic agents. Here, we develop a drug carrier through the attachment of substrate of endoprotease legumain, alanine-alanine-asparagine (AAN), to cell-penetrating peptides (TAT, trans-activating factor). The addition of the AAN moiety to the fourth lysine in the TAT creates a branched peptide moiety, which leads to a decrease in the transmembrane transport capacity of TAT by 72.65%. Legumain efficiently catalyses the release of TAT-liposome from the AAN-TAT-liposome and thereby recovers the penetrating capacity of TAT. Doxorubicin carried by the AAN-TAT-liposome led to an increase in the tumoricidal effect of doxorubicin and a reduction in its systemic adverse effects in comparison with doxorubicin carried by a control delivery system. Thus, the specific targeting and high efficiency of this delivery platform offers a novel approach to limit the toxicity of anticancer agents as well as increasing their efficacy in cancer therapy.

show abstract

“…Several factors have been shown to influence and favor the EPR, for example, prolonged systemic circulation that allows longer interaction of liposomes with the target, size of the liposomes, composition, and charge on the surface of liposomes [12]. Longevity in blood is achieved by coating the liposomes with polymers, such as polyethylene glycol (PEG).…”

Section: Liposomes For Passive Tumor Accumulationmentioning

confidence: 99%

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Porfire¹,

Achim²,

Tefas³

et al. 2017

Liposomes

View full text Add to dashboard Cite

The liposomes present great potential for applications in targeted delivery of chemotherapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for targeting of chemotherapeutic agents to tumor tissues is based on their advantages over other dosage forms, represented by their low systemic toxicity, their bioavailability, and their possibility to enhance the solubility of different chemotherapeutic agents, due to the ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeutic index of anticancer drugs by increasing the drug concentration in tumor cells through tumor targeting. The available approaches used for tumor targeting using liposomes are passive targeting, active targeting, and triggered drug release. The most advanced targeting strategies proposed for cancer treatment are the development of multifunctional liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting mechanisms are described in detail as well as the possibilities to design the targeted liposomal nanocarrier in order to reach the desired target in the body and minimizing the off-target effects. Moreover, the current status of preclinical and clinical evaluation is highlighted.

show abstract

Current Trends in The Use of Liposomes for Tumor Targeting

Cited by 561 publications

References 135 publications

Lysosomal capturing of cytoplasmic injected nanoparticles by autophagy: An additional barrier to non viral gene delivery

Lysosomal capturing of cytoplasmic injected nanoparticles by autophagy: An additional barrier to non viral gene delivery

Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Contact Info

Product

Resources

About